JP2022523514A5 - - Google Patents

Info

Publication number
JP2022523514A5
JP2022523514A5 JP2021544752A JP2021544752A JP2022523514A5 JP 2022523514 A5 JP2022523514 A5 JP 2022523514A5 JP 2021544752 A JP2021544752 A JP 2021544752A JP 2021544752 A JP2021544752 A JP 2021544752A JP 2022523514 A5 JP2022523514 A5 JP 2022523514A5
Authority
JP
Japan
Prior art keywords
optionally
pharmaceutical composition
hla
ncd
proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021544752A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022523514A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/016206 external-priority patent/WO2020160468A1/en
Publication of JP2022523514A publication Critical patent/JP2022523514A/ja
Publication of JP2022523514A5 publication Critical patent/JP2022523514A5/ja
Priority to JP2024231447A priority Critical patent/JP2025062601A/ja
Pending legal-status Critical Current

Links

JP2021544752A 2019-02-01 2020-01-31 神経認知障害を処置するための組成物及び方法 Pending JP2022523514A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024231447A JP2025062601A (ja) 2019-02-01 2024-12-27 神経認知障害を処置するための組成物及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962800177P 2019-02-01 2019-02-01
US62/800,177 2019-02-01
PCT/US2020/016206 WO2020160468A1 (en) 2019-02-01 2020-01-31 Compositions and methods for treating neurocognitive disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024231447A Division JP2025062601A (ja) 2019-02-01 2024-12-27 神経認知障害を処置するための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2022523514A JP2022523514A (ja) 2022-04-25
JP2022523514A5 true JP2022523514A5 (https=) 2023-04-27

Family

ID=71840202

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021544752A Pending JP2022523514A (ja) 2019-02-01 2020-01-31 神経認知障害を処置するための組成物及び方法
JP2024231447A Pending JP2025062601A (ja) 2019-02-01 2024-12-27 神経認知障害を処置するための組成物及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024231447A Pending JP2025062601A (ja) 2019-02-01 2024-12-27 神経認知障害を処置するための組成物及び方法

Country Status (7)

Country Link
US (1) US20220133808A1 (https=)
EP (1) EP3917620A4 (https=)
JP (2) JP2022523514A (https=)
CA (1) CA3127808A1 (https=)
IL (1) IL285270A (https=)
MA (1) MA54880A (https=)
WO (1) WO2020160468A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
WO2019152706A1 (en) 2018-01-31 2019-08-08 Alector Llc Anti-ms4a6a antibodies and methods of use thereof
US11472874B2 (en) 2018-01-31 2022-10-18 Alector Llc Anti-MS4A4A antibodies and methods of use thereof
WO2021067611A2 (en) * 2019-10-01 2021-04-08 Children's Medical Center Corporation Compositions and methods for treating alzheimer's disease
EP4146797A1 (en) * 2020-05-06 2023-03-15 Orchard Therapeutics (Europe) Limited Treatment for neurodegenerative diseases
WO2022006105A2 (en) * 2020-07-02 2022-01-06 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders
US20230265456A1 (en) * 2020-08-10 2023-08-24 Fundacion Para La Investigacion Medica Aplicada Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis
US20220127347A1 (en) * 2020-10-26 2022-04-28 The Regents Of The University Of California Inhibition of Tau Propagation
CA3214688A1 (en) 2021-04-08 2022-10-13 Andrzej KROLEWSKI Methods of diagnosing and predicting renal decline
WO2023156807A2 (en) * 2021-09-27 2023-08-24 Curelab Oncology, Inc. Prevention and treatment of diseases by modulating activity of mesenchymal stem cells with p62 (sqstm1)-encoding vector and pharmaceutical formulations containing p62 (sqstm1) proteins
WO2023108290A1 (en) * 2021-12-15 2023-06-22 The Governing Council Of The University Of Toronto Peptide inhibitors and methods for inhibiting protein aggregation in neurons and neurodegenerative diseases
WO2024178386A1 (en) * 2023-02-24 2024-08-29 Aarhus Universitet Methods of treating endosomal trafficking diseases
AU2024344891A1 (en) * 2023-09-22 2026-04-16 The Board Of Regents Of The University Of Texas System Novel secretory signal peptides and uses thereof
CN117736321A (zh) * 2023-12-20 2024-03-22 中国人民解放军空军军医大学 一种乙酰化修饰的特异性抗体及其应用
WO2025186293A1 (en) * 2024-03-06 2025-09-12 Institut National de la Santé et de la Recherche Médicale Chmp2b mutants for use for treating infection
KR20260001543A (ko) * 2024-06-25 2026-01-06 연세대학교 산학협력단 바이러스 벡터를 포함한 난청 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000002911A2 (en) * 1998-07-10 2000-01-20 Curagen Corporation INTERACTION OF HUMAN BETA AMYLOID PRECURSOR PROTEIN (β-APP) WITH HUMAN LON-PROTEASE LIKE PROTEIN (HSLON)
EP1461087A1 (en) * 2001-12-06 2004-09-29 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders
US20130102538A1 (en) * 2010-05-05 2013-04-25 Amicus Therapeutics, Inc. Method of treating alzheimer's disease using pharmacological chaperones to increase presenilin function and gamma-secretase activity
JP2016537995A (ja) * 2013-11-05 2016-12-08 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 新しいアルツハイマー病動物モデル
WO2017147509A1 (en) * 2016-02-25 2017-08-31 Marco Colonna Compositions comprising trem2 and methods of use thereof
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
KR102040364B1 (ko) * 2017-05-26 2019-11-05 가천대학교 산학협력단 알츠하이머병 관련 ３０개 유전자를 이용한 유전적 진단방법
BR112020001060A2 (pt) * 2017-07-27 2020-07-14 Novartis Ag variantes de trem2 resistentes a shedase

Similar Documents

Publication Publication Date Title
JP2022523514A5 (https=)
JP2022523913A5 (https=)
US11965174B2 (en) Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
AU2015364636B9 (en) Gene therapy for Juvenile Batten Disease
JP2025015673A (ja) 脊髄軟膜下遺伝子送達システム
Iida et al. Systemic delivery of tyrosine‐mutant AAV vectors results in robust transduction of neurons in adult mice
CA3134841A1 (en) Gene therapies for lysosomal disorders
US20250136994A1 (en) Compositions and methods to restore paternal ube3a gene expression in human angelman syndrome
JP2021517168A5 (https=)
US20230190893A1 (en) Compositions and methods for treating an inherited retinal disease
Minskaia et al. Viral vectors in gene replacement therapy
Hoshino et al. The adeno-associated virus rh10 vector is an effective gene transfer system for chronic spinal cord injury
Chatterjee et al. Adeno-associated virus and hematopoietic stem cells: the potential of adeno-associated virus hematopoietic stem cells in genetic medicines
JP2022523123A5 (https=)
JP2021526839A (ja) 眼圧及び頭蓋内圧を調節するための材料及び方法
US20250171778A1 (en) Treatments of Disorders of Myelin
US20240408243A1 (en) Methods for upregulating shank3 expression
JP2025513887A (ja) 肝臓における遺伝子発現を脱標的化するための要素
Cagin Targeting age-related neurodegenerative diseases by AAV-Mediated gene therapy
CN117561331A (zh) 用于产生经基因修饰的原代细胞的方法和组合物
CN115702246A (zh) 调节性核酸序列
US20240156873A1 (en) Methods to genetically engineer hematopoietic stem and progenitor cells for red cell specific expression of therapeutic proteins
US20240366680A1 (en) Treatment of pain
WO2024226729A2 (en) Compositions and methods for opa1 gene therapy
HK40049414A (en) Adeno-associated virus vector variants for high efficiency genome editing and methods thereof